OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma
OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121 in Recurred, Resected Osteosarcoma with OST-HER2 (Listeria monocytogenes) for Delay or Prevention of Recurrence
OS Therapies Receives Rare Pediatric Disease Designation (RDD) in Osteosarcoma for OST-HER2 (Listeria monocytogenes)
OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma
OS Therapies Completes $6 Million Series A Funding Round to Fund OST-HER2 PhIIb Trial and OST-tADC Preclinical Next Generation ADC
OS Therapies Receives Trial Approval From Children's Oncology Group for AOST2121 / OST31-164-01
Dr. Jutta Wanner Joins Her Next Generation ADC Technology at OS Therapies as Chief Technology Officer
OST Acquires BlinkBio’s Next Generation ADC Technology Platform
OS Therapies to relocate at Eastern Shore Innovation Center in Cambridge, MD
Dr. Robert Petit Follows His Passion to OS Therapies as Chief Medical & Scientific Advisor
